NIELSENIQ
9.11.2021 07:03:09 CET | Business Wire | Press release
NielsenIQ BASES is delighted to announce today the launch of its 2021 annual Breakthrough Innovation Report which awards the most successful consumer packaged goods product launches.
The report, which celebrates its 10th anniversary this year, has unveiled the leading innovations of the FMCG world that have made the biggest impact. The brands that made the list reflect a wide range of products and approaches that succeeded in making meaningful connections with consumers, an impressive feat within an increasingly crowded marketplace.
Of the 98 European winners named in the report over the last decade, over 90% percent are still in the market today. When you compare this figure to the regularly used statistic of 90% of new launches failing to survive beyond two years, this demonstrates that NielsenIQ BASES has got its finger on the pulse when it comes to identifying the winning formula for new product launches.
This year's 25 European cross-category winners include representation across multiple markets including UK, France, Germany, Italy, Norway, Russia, Poland, Spain, Switzerland and the Netherlands. This year, these products were overwhelmingly dominated by line extensions, with nearly all of the winners (96%) coming from existing brands. Among the factors defining their success, the winners saw an 86% average value sales increase from Year 1 to Year 2. This is all the more impressive when you consider typically more than half of new products decline in their second year in market.
Celine Grena, European BASES leader, comments: “It is worth noting that when you go back to the first report launched 10 years ago, trends such as ‘shopping locally’, sustainability and convenience were the ‘ones to watch’. While these trends still exist, a number of these are gradually crystallising into the standout theme of mindful living. In fact, over half of the winners this year have at least one mindful living claim, versus only about one quarter in 2019.”
Findings also show that demand for environmentally conscious products is growing and able to drive premiumisation. Consumers are looking for products that use natural ingredients and more sustainable formulations. And whilst it does not have to be the core of the proposition for some brands, waste reduction or a more sustainable production cycle are key trends within the winners.
Alcoholic beverages find success through attracting category buyers to their brand for the first time or opening up new consumption occasions for the brand. In other beverages and food, the focus is on ingredients with added health benefits to support the mind and body. This trend is leading to consumers actively look for low-sugar, -salt, -carb, - calorie and -fat when buying products. This trend is not confined to humans, our beloved pets are also getting products that tap into this demand with ‘free-from’ credentials.
Transparency is another important factor across categories, with clean (64%), locally grown (52%) and ethically sourced (39%) ingredients the top claims that would most impact brand trust. Consumers want to know what they are consuming, where it is coming from and how it impacts their health, so brands will need to put more emphasis on transparency to achieve sales success in the future.
Grena, continues: “Through this year’s winners, we can see that while health and wellness remains an important area of focus, sustainability is increasing in importance within the European market amid growing concerns about climate change. As this trend gathers pace manufacturers will need to respond to this rising social issue through innovative packaging design, and raising awareness of environmentally conscious credentials, to drive impact for new product launches. Premiumisation is another key area we’re seeing develop, both from a packaging and product performance perspectives, with many consumers willing to pay more for these benefits.”
European Winners (listed in alphabetical order):
- Aspi Gola (Italy)
- Birds Eye Green Cuisine (UK)
- Birra Messina Cristalli Di Sale (Italy)
- Butcher’s Tripe Loaf (UK)
- Cadbury Darkmilk (UK)
- Costa Coffee Ready-to-Drink (UK)
- Febreze Bathroom Air Freshener (UK)
- Finish Quantum Ultimate (UK & Germany)
- Hansa Mango IPA (Norway)
- Hanuta Riegel (Germany)
- Innocent Plus (UK & France)
- J.J Whitley – Artisanal Russian Vodka (UK)
- Leffe d'Été (France)
- Magnum Vegan (UK & Germany)
- Martini Fiero (Russia)
- Pampers Harmonie (France)
- Persil 4-in-1 discs (Germany)
- Pringles Rice Fusion (UK)
- Rimmel Lasting Radiance (UK)
- Scholl Dry Skin Foot Mask (Germany)
- Sensodyne Sensitivity & Gum (UK)
- Somersby Mango i Limonka (Poland)
- Starbucks for Nespresso (UK, France, Switzerland, Netherlands and Spain)
- This Isn’t (UK)
- Whiskas Pure Delight (UK)
ENDS
For further information, please contact Publicasity at NielsenIQ@publicasity.co.uk
About NielsenIQ BASES Breakthrough Innovation
This year’s Breakthrough Innovation process reviewed over 50,000 product launches. The brands that made the 2021 list reflect a wide range of products and approaches that succeeded in making meaningful connections with consumers, an impressive feat within an increasingly crowded marketplace. Beyond BASES requirements for products that reflect strong, distinct qualities such as mass potential, longevity, brand incrementality, category distinction or appeal toward a specific consumer target, this year’s list brings the continued evolution of the success criteria, which includes all six of NielsenIQ BASES’ activation profiles.
About NielsenIQ
NielsenIQ is the leader in providing the most complete, unbiased view of consumer behavior, globally. Powered by a groundbreaking consumer data platform and fueled by rich analytic capabilities, NielsenIQ enables bold, confident decision-making for the world’s leading consumer goods companies and retailers.
Using comprehensive data sets and measuring all transactions equally, NielsenIQ gives clients a forward-looking view into consumer behavior in order to optimize performance across all retail platforms. Our open philosophy on data integration enables the most influential consumer data sets on the planet. NielsenIQ delivers the complete truth.
NielsenIQ, an Advent International portfolio company, has operations in nearly 100 markets, covering more than 90% of the world’s population. For more information, visit NielsenIQ.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20211108006185/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
LabPMM® Launches Global KMT2A MRD Testing Service to Support Menin Inhibitor Development and Acute Leukemia Care4.8.2026 09:10:00 CEST | Press release
LabPMM®, an Invivoscribe® subsidiary, today announced the global availability of its new KMT2A measurable residual disease (MRD) testing service. The highly sensitive digital PCR service is available to healthcare providers, clinical researchers, and biopharmaceutical partners through LabPMM’s global laboratory network, with CAP/CLIA-accredited testing available in the U.S. The service addresses a growing need for accurate molecular monitoring in acute leukemias.1,2,3 KMT2A rearrangements (KMT2Ar) are oncogenic drivers in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).4 These rearrangements are present in about 80% of infant cases and 5-15% of childhood and adult leukemia cases.5 KMT2Ar leukemias are associated with chemotherapy resistance, high relapse rates, and poor clinical outcomes.5 The emergence of menin inhibitors is transforming the therapeutic landscape for patients with AML and ALL, particularly those with KMT2A-rearranged and NPM1-mutated disease.6 The
“HATSUNE MIKU LIGHTS TOKYO” Debuts on July 254.8.2026 09:00:00 CEST | Press release
Giant Hatsune Miku Returns to Light Up Tokyo’s Night! The Tokyo Metropolitan Government has been presenting year-round projection mapping displays on the Tokyo Metropolitan Government Building, using light and sound to showcase a wide range of artistic expressions as part of its efforts to create new nighttime tourism attractions in Tokyo. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260802298570/en/ © Crypton Future Media, INC. On Saturday, July 25, "HATSUNE MIKU LIGHTS TOKYO", featuring the globally beloved virtual singer Hatsune Miku, held its first screening. The work brings the world of the popular song “M@GICAL☆CURE! LOVE ♥ SHOT!” to life across the entire façade of the Tokyo Metropolitan Government Building. Since its launch in February 2024, “TOKYO Night & Light” has welcomed visitors from Japan and around the world, with total attendance surpassing 1.55 million. As one of Tokyo’s emerging landmark attractions, the
Mosaic Therapeutics appoints Dr Allison Jeynes as Chair of the Board4.8.2026 09:00:00 CEST | Press release
Accomplished life sciences leader with a proven track record of driving successful development of novel therapeutics, joins Mosaic to guide its next phase of growthAllison brings three decades of drug development, board and executive leadership experience to support Mosaic’s transition towards a clinical-stage company Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) an oncology therapeutics company developing novel, targeted drug combinations across a range of haematological and solid cancers, today announced the appointment of Dr Allison Jeynes as Chair of the Board to support its next phase of growth and advancement towards clinical development. Allison succeeds Dr Edward Hodgkin, who remains a Non-Executive Director of the Board. Allison is a UK-trained oncologist and highly-experienced life sciences leader, and brings over three decades of drug development and executive experience to Mosaic Therapeutics. As CEO of Avillion, a clinical development company, for the last 13 year
TOHKnet and Adtran conduct Japan’s first 50G PON trial on a live network4.8.2026 09:00:00 CEST | Press release
News summary: TOHKnet is exploring next-generation PON to meet enterprise demand while maintaining continuity across its regional fiber network Using Adtran technology, the trial validated 50G PON, XGS-PON and EPON operating together on a single fiber network Results show a practical path to evolve networks, enabling phased upgrades while maximizing fiber assets and avoiding service disruption Adtran today announced that TOHKnet has completed Japan’s first live network trial demonstrating the coexistence of 50G PON, XGS-PON and EPON on a single fiber. Conducted in Sendai using Adtran’s SDX 6400 Series OLT, the demo showed how the platform enables three generations of PON technology to operate together in a live service environment. The results highlight a realistic path for operators to introduce 50G PON capacity while maintaining continuity for existing services, maximizing the value of deployed fiber assets and reducing the complexity and disruption typically associated with network
Evexta Bio Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate Rupitasertib in Combination with a Selective Estrogen Receptor Degrader in Advanced / Metastatic Breast Cancer4.8.2026 09:00:00 CEST | Press release
Study to evaluate rupitasertib, Evexta Bio’s first-in-class oral dual-node, S6K and AKT1/3 inhibitor in combination with giredestrant in second-line ER+, HER2-, ESR1-mutated advanced / metastatic breast cancer; expected to initiate in Q4 2026First clinical collaboration and supply agreement for Evexta Bio with rupitasertib and for Roche with giredestrant; results to inform future strategy for rupitasertib combination in ER+ HER2- advanced /metastatic breast cancer Evexta Bio S.A., a precision oncology company, founded by Truffle Capital (founder of Abivax and Carvolix), and focused on the discovery and development of targeted therapies, today announced a clinical collaboration and supply agreement with plans to initiate a Phase 1b study combining its lead investigational compound, rupitasertib, with Roche’s investigational compound giredestrant, a selective estrogen receptor degrader (SERD), for the treatment of ER+, HER2-, ESR1-mutated advanced / metastatic breast cancer. Rupitasertib
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
